Company intelligence
NanoMosaic Inc.
Next generation proteomics and multi-omics powered by nanoneedles
Biotechnology Research
Waltham, US
16 employees
3 public signals
About NanoMosaic Inc.
Next generation protein interrogation powered by nanoneedles, enabling early disease detection, prognostic monitoring and biomarker discovery on a single chip.
Verified activity
Signals from NanoMosaic Inc.
3 published signals
Capital & Finance
NanoMosaic Inc. joined the Mass General Hospital consortium as one of five teams selected to receive up to $125 million in total funding under ARPA-H's GIVE program.
Reported by NanoMosaic Inc.
Research & Knowledge
NanoMosaic Inc. published a case study showing that sequence-specific genome mapping measured the true full-length population at approximately 4% in a commercially sourced AAV9 sample.
Reported by NanoMosaic Inc.
Legal & Regulatory
NanoMosaic Inc. noted that the FDA/CBER released a new draft guidance titled Potency Assessment of Active Immunotherapy Products, applying to active immunotherapies including certain vectored products using viral vectors, DNA or RNA to deliver sequences that express target antigens.
Reported by NanoMosaic Inc.